Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Ranbaxy’s $500 Million GMP Settlement Would Be Second Most Expensive For Rx Manufacturing Violations

This article was originally published in The Pink Sheet Daily

Executive Summary

Ranbaxy Laboratories said it has signed a consent decree with FDA and set aside $500 million to settle a related Department of Justice investigation involving GMP violations and data integrity issues at its Indian facilities.

You may also be interested in...



Generic Lipitor Era Dawns With Watson’s Launch, Followed By Ranbaxy’s Last-minute Approval

Teva will share in Ranbaxy’s profits during its exclusivity period, as FDA announces approval of Ranbaxy’s first-filed ANDA more than 14 hours after Watson discloses that it began shipping its atorvastatin “authorized generic”.

GSK’s $750 Mil. DoJ Settlement: When GMP Violations Equal Healthcare Fraud

GlaxoSmithKline’s $750 million settlement with the Department of Justice raises a worrisome question for industry: will violations of current good manufacturing practices become a target for whistleblower suits?

Schering NDAs Are Clear For Review Under FDA Consent Decree

Schering-Plough NDAs will not be subject to extra scrutiny under the GMP consent decree with FDA

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS073200

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel